FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience

Affiliations

• ¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
• ² Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
• ³ Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL.
• ⁴ Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ.
• ⁵ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN. kaufmann.scott@mayo.edu.
• ⁶ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN. alkali.aref@mayo.edu.